Zidesamtinib Shows 93% Response Rate in ROS1-Positive Lung Cancer

The ARROS-1 global trial revealed promising results for zidesamtinib, a new targeted therapy achieving a 93% response rate in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received tyrosine kinase inhibitors (TKIs). ROS1-positive lung cancer represents a specific genetic subtype affecting approximately 1-2% of NSCLC patients. These findings, presented at the 2026 International Association for the Study of Lung Cancer World Conference, offer hope for improved treatment options in this patient population. This breakthrough could significantly extend survival and improve quality of life for patients with this rare but aggressive lung cancer variant.

Originally published on
Medical Xpress
Read full article(opens in new tab)Fetched: September 14, 2026 at 10:01 AM



